The deal positions MilliporeSigma at the center of commercial manufacturing for three breakthrough gene therapies targeting sickle cell disease, ?-thalassemia, and cerebral adrenoleukodystrophy
Outlines 1,500-member internal cadre, digital regulatory system, and faster SEC-led reviews
Under the deal, Quiver will receive an undisclosed advance payment and research support
Dr Adams’ lab recently uncovered a novel cellular detoxification pathway driving Cisplatin resistance in NSCLC
Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation
Under his leadership, Chidamide became China’s first original small-molecule anti-tumor innovative drug and the country’s first pharmaceutical product globally licensed out
SandboxAQ will receive an upfront payment and could earn up to $200 million in milestone payments tied to preclinical, development, regulatory, and commercial achievements
Patients with BRCA mutations often face aggressive disease and poor prognosis
Soficitinib is a potent and selective TYK2 inhibitor under development for multiple T-cell mediated autoimmune disorders
Topline results from the Phase 2 VISTA trial show that PIPE-307 did not meet its primary or secondary efficacy endpoints
Subscribe To Our Newsletter & Stay Updated
